Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NPS isovaleramide migraine study

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

NPS' alifatic amide neuromodulator isovaleramide (NPS 1776) fails to show significance in a proof-of-concept study in moderate to severe migraine "due to a higher than expected placebo response," NPS says Oct. 11. A positive response was seen in 60% of patients receiving a high dose (800 mg), 64% receiving a low dose (400 mg), and 56% of placebo patients in the 189-patient Phase IIa trial. NPS "will complete its evaluation of data from this study, and plans to continue to explore the development of NPS 1776 in other indications." Other potential indications for isovaleramide include bipolar disorder and epilepsy...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS002708

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel